Tandem Diabetes Care, Inc. — FY2022 Form 10-K
Business context and reporting period. Tandem designs and sells diabetes-management technology, principally its t:slim X2 insulin pump, related disposable cartridges and infusion sets, and supporting software. This annual report covers the fiscal year ended December 31, 2022; fourth-quarter results are unaudited. Products were available in approximately 25 countries. The company estimated its four-year global installed pump base at approximately 420,000, up 29% year over year.
Key financial results
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $801.2 million | $702.8 million |
| Gross profit / margin | $413.0 million / 52% | $376.2 million / 54% |
| Operating income (loss) | ($92.8 million) | $22.7 million |
| Net income (loss) | ($94.6 million) | $15.6 million |
| Operating cash flow | $50.5 million | $111.4 million |
- Revenue rose 14%. U.S. sales increased 12% to $588.8 million; sales outside the U.S. rose 19% to $212.5 million, about 27% of total revenue.
- Supply sales drove growth: U.S. infusion-set and cartridge sales increased 29% and 27%, respectively; international sales increased 35% and 36%. Pump shipments were approximately flat in both U.S. and international markets.
- Gross margin declined two percentage points. Higher average selling prices and manufacturing efficiencies partly offset product mix, COVID-related pressures, higher material and freight costs, and the Tandem Choice program.
- Operating expenses increased 43% to $505.8 million, including SG&A of $335.7 million, R&D of $139.1 million, and $31.0 million of acquired in-process R&D expense. Higher staffing and development investment contributed to expense growth.
- Fourth-quarter revenue was $220.5 million versus $210.0 million. Gross profit was $115.5 million; operating loss was $17.8 million and net loss was $15.9 million, compared with operating income of $12.7 million and net income of $10.8 million in Q4 2021.
Liquidity, cash flow and debt
- At year-end, cash, cash equivalents and short-term investments totaled $616.9 million. Current assets were $850.0 million and current liabilities $165.3 million.
- Operating cash flow fell to $50.5 million from $111.4 million, reflecting the net loss and working-capital changes, including inventory growth to $111.1 million from $68.6 million.
- Capital expenditures were $34.1 million. Investing cash flow was positive $33.2 million, primarily reflecting net maturities of short-term investments and offset by capital spending and acquisitions.
- The company had $287.5 million principal amount of 1.50% convertible notes due May 2025; the balance-sheet carrying amount was $283.2 million. The $100 million revolving credit facility had no borrowings and $95.1 million available after letters of credit. The notes are senior unsecured; the revolver is secured by substantially all company assets and has financial covenants.
Changes, outlook and notable items
- The company reported a swing from FY2021 net income to a FY2022 net loss, despite revenue and gross-profit growth. Increased SG&A, R&D, and acquired IPR&D drove the operating loss.
- In September 2022, Tandem launched Tandem Choice, allowing eligible U.S. customers to access a future hardware platform for a fee. FY2022 revenue included a $3.5 million deferral; $6.8 million was allocated to the program right and recorded as deferred revenue. Management said the program’s total financial impact cannot yet be estimated.
- FY2022 included a $31.0 million charge related to the Capillary Biomedical asset acquisition and a $12.4 million fourth-quarter facilities consolidation charge; the latter included fixed-asset disposal and lease-related costs.
- Management said elevated supply-chain and material-cost pressure was expected to continue into the first half of 2023, and distributor inventory adjustments following the European distribution-center launch could affect European sales through mid-2023. The filing provides no specific quantified revenue or earnings guidance.
- Product development priorities include Mobi, t:slim X3, extended-wear infusion sets, expanded Control-IQ indications, and integrations with Dexcom G7 and Abbott CGM systems. Timing and commercialization remain subject to development and regulatory approvals.
- Risks emphasized include competition, reimbursement and customer retention, reliance on third-party suppliers and distributors, component shortages, regulatory and product-safety requirements, cybersecurity and privacy, foreign-exchange exposure, and the company’s history of losses. Two U.S. distributors represented approximately 20% of worldwide sales; the top three distributors outside the U.S. represented about 50% of international sales.
- The company completed the AMF Medical acquisition in January 2023 after year-end, including CHF 62.4 million paid at closing and up to CHF 129.6 million in contingent earnouts tied to development and FDA milestones.
Important facts for investors to verify
- Whether installed-base growth converts into sustained pump and recurring supply sales, particularly as U.S. customer replacement cycles mature.
- The effect of Tandem Choice accounting, customer elections, future hardware launch timing, and deferred revenue on reported revenue and margins.
- Whether supply costs, component availability, inventory levels, and European distributor ordering normalize as management expects.
- Progress and costs for Mobi, Sigi, extended-wear infusion sets, CGM integrations, and expanded Control-IQ indications, including required regulatory clearances.
- Liquidity and cash generation relative to the 2025 convertible-note maturity, the revolver’s covenants, and AMF earnout obligations.
- The $36.5 million pump warranty reserve is a significant estimate; the auditor identified replacement-rate assumptions as a critical audit matter. Also monitor the outcome of any appeal in the phishing-related lawsuit, which was dismissed at the trial court level in February 2023.